Departments of Hepatobiliary Surgery, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China.
Eur Rev Med Pharmacol Sci. 2022 Apr;26(8):2647. doi: 10.26355/eurrev_202204_28592.
Correction to: European Review for Medical and Pharmacological Sciences 2020; 24 (7): 3586-3591-DOI: 10.26355/eurrev_202004_20820-PMID: 32329833, published online on 15 April 2020. After publication, the authors noticed some mistakes in the manuscript and applied to issue the following changes: the legend of Table I, the date of enrollment of the patients in the section titled "Baseline Characteristics of HCC Patients", the date of follow-up reported in the abstract and in the section entitled "Postoperative Follow-Up". The authors also applied to modify the survival curve of Figure 3 due to misuse of data in the statistical analysis. There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/20820.
欧洲医学与药物科学评论 2020;24(7):3586-3591-DOI:10.26355/eurrev_202004_20820-PMID:32329833,于 2020 年 4 月 15 日在线发表。发表后,作者发现手稿中有一些错误,并提出发布以下更正:表 I 的说明,标题为“肝癌患者的基线特征”部分中患者的入组日期,摘要中和题为“术后随访”部分中报告的随访日期。作者还申请修改图 3 的生存曲线,因为在统计分析中误用了数据。本文有修订。出版商对由此造成的任何不便表示歉意。https://www.europeanreview.org/article/20820.